PharmaSGP Holding SE Logo

PharmaSGP Holding SE

Develops and markets leading natural OTC drugs for chronic conditions in the European market.

PSG | F

Overview

Corporate Details

ISIN(s):
DE000A2P4LJ5
LEI:
3912005CZ12PVVCIPT91
Country:
Germany
Address:
Lochhamer Schlag 1, 82166 Gräfelfing
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of leading over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive remedies based on natural pharmaceutical active ingredients with documented efficacy and minimal known side effects. Its core brands are market leaders in Germany and other European countries for chronic indications, including rheumatic and nerve pain (RubaXX®, Restaxil®), sleep disorders (Baldriparan®), and sexual weakness (DESEO®, NERADIN®). Since launching its first product in 2012, PharmaSGP has expanded its business model across Europe. The company's growth is driven by organic brand development and strategic acquisitions, such as its 2021 purchase of an OTC brand portfolio from GSK.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-22 15:15
Pre-Annual General Meeting Information
PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out
English 7.3 KB
2025-09-19 14:15
Report Publication Announcement
English 3.9 KB
2025-09-11 09:00
Earnings Release
PharmaSGP publishes preliminary half-year figures for 2025
English 15.7 KB
2025-08-14 12:00
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,315 additional shares…
English 6.8 KB
2025-08-11 13:00
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 39,678 additional share…
English 6.8 KB
2025-08-08 11:47
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 873 additional shares o…
English 6.8 KB
2025-08-07 13:11
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,505 additional shares…
English 6.8 KB
2025-08-06 16:16
Delisting Announcement
PharmaSGP Holding SE: Delisting of PharmaSGP shares from Frankfurt Stock Exchan…
English 7.8 KB
2025-08-05 10:48
Director's Dealing
PharmaSGP Holding SE: Michael Rudolf, Tender of 4,169 shares within the public …
English 5.9 KB
2025-08-04 13:58
Delisting Announcement
PharmaSGP Holding SE: Dr. Clemens Fischer, Tender of a total of 6,062 addition…
English 6.6 KB
2025-07-28 17:04
Delisting Announcement
PharmaSGP Holding SE publishes joint reasoned statement of the Management Board…
English 9.2 KB
2025-07-28 14:11
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of an additional total of 4,491 share…
English 6.9 KB
2025-07-24 15:30
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, buy
English 6.0 KB
2025-07-24 14:11
Delisting Announcement
FUTRUE GmbH submits request to implement squeeze-out of minority shareholders o…
English 8.2 KB
2025-07-23 17:38
Declaration of Voting Results & Voting Rights Announcements
English 13.0 KB

Automate Your Workflow. Get a real-time feed of all PharmaSGP Holding SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PharmaSGP Holding SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-25 FUTRUE GmbH Close relation Buy None 12,145,250.00 EUR
2022-10-05 MMI Leisure & Capital Management GmbH Close relation Buy None 125,383.20 EUR
2022-10-05 Hillen, Ingo Board Buy None 1,048.00 EUR
2022-10-05 MMI Leisure & Capital Management GmbH Close relation Buy None 26.60 EUR
2022-05-30 Wittig, Dr. Thomas Supervisory board Buy None 138,953.80 EUR
2022-05-30 Schröter, Jasmin Close relation Buy None 119,660.00 EUR
2022-05-30 Simon-Schröter, Dr. Wolfram Other Buy None 10,040.00 EUR
2022-04-25 FUTRUE GmbH Close relation Buy None 208,180.53 EUR
2022-04-25 MMI Leisure & Capital Management GmbH Close relation Sell None 197,193.60 EUR
2022-04-25 Bloching, Prof. Dr. Micha Supervisory board Sell None 171,825.00 EUR

Peer Companies

Company Country Ticker View
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan 4503

Talk to a Data Expert

Have a question? We'll get back to you promptly.